Company news
Alx Oncology Holdings Inc. (NASDAQ:ALXO) news
Every Alx Oncology Holdings Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel
June 30, 2026
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York
June 1, 2026
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 8, 2026
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Ca...
April 30, 2026
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
April 17, 2026
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer
April 13, 2026
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 2, 2026
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
February 27, 2026
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026
February 19, 2026
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026
February 19, 2026
ALX Oncology Announces Pricing of Underwritten Offering
January 30, 2026
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-h...
January 30, 2026
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 8, 2026
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug...
January 8, 2026
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Stand...
December 7, 2025
ALX Oncology to Present at Upcoming Investor Conferences
November 18, 2025
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 7, 2025
ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presente...
October 30, 2025
ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-N...
October 23, 2025
ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric...
October 3, 2025
ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer
September 12, 2025
ALX Oncology to Participate in Upcoming Investor Conferences in September
August 29, 2025
ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors
August 19, 2025
ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 12, 2025
ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025
August 5, 2025
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference
May 30, 2025
ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event
May 20, 2025
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025
May 13, 2025
ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 8, 2025
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025
May 2, 2025
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment ...
April 25, 2025
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and...
April 25, 2025
ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate
April 7, 2025
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
March 6, 2025
ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event
March 5, 2025
ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
February 27, 2025
ALX Oncology to Host Virtual R&D Day on March 5, 2025
February 18, 2025
ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Cl...
January 23, 2025
ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Offic...
January 22, 2025
ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI
January 21, 2025
ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer ...
December 18, 2024
ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanc...
December 10, 2024
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
November 14, 2024
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 7, 2024
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio B...
November 1, 2024
ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
September 9, 2024
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
September 4, 2024
ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 8, 2024
ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
August 6, 2024
ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Posi...
July 31, 2024